Jazz, Hikma Must Face Bulk Of Xyrem Antitrust Suit

By Bryan Koenig · August 28, 2024, 7:33 PM EDT

Jazz Pharmaceuticals and Hikma Pharmaceuticals appear bound for trial against most solo insurer and class action antitrust claims over alleged efforts to block generic competitors to Jazz's Xyrem narcolepsy drug, under...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In re Xyrem (Sodium Oxybate) Antitrust Litigation

Case Number

3:20-md-02966

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

December 16, 2020

Featured Stories

Tupperware's Crash Unseals Lenders' Foreclosure Dreams No Photo Available

Vince Sullivan

Iconic food storage product maker Tupperware Brands Corp. filed for Chapter 11 in mid-September with critically low liquidity, and now... (more story)

J&J Has An Uphill Battle To Keep Newest Ch. 11 In Texas No Photo Available

Vince Sullivan

Consumer products giant Johnson & Johnson is facing significant pushback for filing its third bankruptcy in yet another new venue as i... (more story)

Rate Cuts Offer Balm For Companies Teetering On Bankruptcy No Photo Available

Alex Wittenberg

The Federal Reserve's jumbo interest rate cut last week has lifted hopes that cheaper debt and a potential soft landing will let compa... (more story)